Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NanoViricides Inc (NNVC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: NNVC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.12% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.27M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 1 | Beta 1.16 | 52 Weeks Range 0.94 - 1.92 | Updated Date 10/17/2025 |
52 Weeks Range 0.94 - 1.92 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -55.39% | Return on Equity (TTM) -99.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19456512 | Price to Sales(TTM) - |
Enterprise Value 19456512 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.11 | Shares Outstanding 17431000 | Shares Floating 16863621 |
Shares Outstanding 17431000 | Shares Floating 16863621 | ||
Percent Insiders 3.45 | Percent Institutions 7.66 |
Upturn AI SWOT
NanoViricides Inc
Company Overview
History and Background
NanoViricides, Inc. was founded in 2005 and focuses on developing drugs for viral infections based on its nanoviricide technology. The company has progressed through preclinical stages and some early clinical trials but has not yet brought a product to market.
Core Business Areas
- Antiviral Drug Development: Development of novel antiviral drugs using its nanoviricide platform technology.
Leadership and Structure
Dr. Anil R. Diwan is the Chairman, President, and CEO. The company has a small management team and a scientific advisory board.
Top Products and Market Share
Key Offerings
- Nanoviricides Technology Platform: The core technology is designed to mimic cell surface receptors to attract viruses, then disable them and prevent infection. No market share as there are no currently marketed products. Competitors: Companies developing traditional antiviral drugs and novel antiviral therapies.
Market Dynamics
Industry Overview
The antiviral drug market is large and growing, driven by the emergence of new viral threats and the increasing prevalence of existing viral infections. This also includes treatments for unmet needs in areas such as shingles and influenza.
Positioning
NanoViricides is a biotechnology company attempting to establish a unique position with its nanoviricide platform. It aims to address viral infections where current treatments are inadequate. NanoViricides is positioned against large pharma and other biotechs creating antiviral drugs using traditional methods.
Total Addressable Market (TAM)
The global antiviral drug market is estimated to be in the tens of billions of dollars annually. NanoViricides aims to capture a portion of this market with its novel approach, but currently has no revenue. TAM is large; NanoViricides' success in addressing TAM depends on successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Novel technology platform with potential for broad-spectrum antiviral activity
- Potential to address unmet needs in viral infections
- Proprietary technology and intellectual property
Weaknesses
- Lack of approved products and revenue
- High dependence on external funding
- Limited clinical trial data
- Relatively small size and limited resources
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of nanoviricide platform to new viral targets
- Favorable regulatory environment for innovative antiviral therapies
Threats
- Competition from established antiviral drugs and therapies
- Clinical trial failures
- Funding challenges
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- GILD
- JNJ
- MRK
- ABBV
Competitive Landscape
NanoViricides faces intense competition from established pharmaceutical companies with significantly greater resources and approved antiviral products. Its competitive advantage lies in its novel technology, but it must demonstrate clinical efficacy and safety to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited, as the company is pre-revenue and focused on R&D.
Future Projections: Future growth is highly dependent on the successful development and commercialization of its nanoviricide technology. Analyst estimates are not readily available due to the company's speculative nature.
Recent Initiatives: Focus on advancing its lead drug candidates through clinical trials, securing funding, and seeking partnerships.
Summary
NanoViricides is a high-risk, high-reward biotechnology company with a novel antiviral technology. Its success depends on positive clinical trial results and securing adequate funding. The lack of revenue and strong competition are significant challenges, but the company's unique approach could offer substantial returns if successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and due diligence. This is an AI generated analysis and may be subject to errors and omissions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NanoViricides Inc
Exchange NYSE MKT | Headquaters Shelton, CT, United States | ||
IPO Launch date 2005-10-26 | Executive Chairman, President, CEO & Secretary Dr. Anil R. Diwan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.nanoviricides.com |
Full time employees 7 | Website https://www.nanoviricides.com | ||
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.